Actoplus Met (Pioglitazone HCl/Metformin HCl) Patent Expiration, LOE Window & CMS Spending
Actoplus Met (Pioglitazone HCl/Metformin HCl) by Takeda: FDA Orange Book LOE 2029-02-03, 4 AB generics, $125K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Takeda |
| FDA Application & Pathway | N021842 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2029-02-03 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $125K |
| 2024 Medicare Part D Spend | $112K |
| 2024 Medicaid Spend | $14K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.